Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Nature Reviews Drug Discovery 17, 280 (2018).
doi:10.1038/nrd.2017.221
Authors: Elizabeth M. Berry-Kravis, Lothar Lindemann, Aia E. Jønch, George Apostol, Mark F. Bear, Randall L. Carpenter, Jacqueline N. Crawley, Aurore Curie, Vincent Des Portes, Farah Hossain, Fabrizio Gasparini, Baltazar Gomez-Mancilla, David Hessl, Eva Loth, Sebastian H. Scharf, Paul P. Wang, Florian Von Raison, Randi Hagerman, Will Spooren & Sébastien Jacquemont
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene, FMR1,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Elizabeth M. Berry-Kravis Lothar Lindemann Aia E. J ΓΈ nch George Apostol Mark F. Bear Randall L. Carpenter Jacqueline N. Crawley Aurore Curie Vincent Des Portes Farah Hossain Fabrizio Gasparini Baltazar Gomez-Mancilla David Hessl Eva Loth Sebastian H. Sc Tags: Review Source Type: research
More News: Autism | Brain | Disability | Drugs & Pharmacology | Fragile X Syndrome | Genetics | International Medicine & Public Health | Lessons | Neurology